Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas S Heitmann

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|March 15, 2022
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALLNaveen K Mehta, Martin Pfluegler, Kristan Meetze, et al.
Journal of Hematology & Oncology|August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual diseaseJonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Nature Communications|October 4, 2017
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemiaMelanie Märklin, Jonas S Heitmann, Alexander R Fuchs, et al.
Cancer Discovery|May 20, 2021
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with CancerTatjana Bilich, Malte Roerden, Yacine Maringer, et al.
EMBO Molecular Medicine|December 29, 2020
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancerLatifa Zekri, Fabian Vogt, Lukas Osburg, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsClaudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Frontiers in Immunology|December 11, 2024
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patientsJonas S Heitmann, Susanne Jung, Marcel Wacker, et al.
Clinical Therapeutics|February 7, 2026
Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19Maddalena Marconato, Christopher Hackenbruch, Simon Jäger, et al.
Nature Communications|November 18, 2023
TOF<sub>IMS</sub> mass spectrometry-based immunopeptidomics refines tumor antigen identificationNaomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
Nature|November 23, 2021
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunityJonas S Heitmann, Tatjana Bilich, Claudia Tandler, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|March 15, 2022
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALLNaveen K Mehta, Martin Pfluegler, Kristan Meetze, et al.
Journal of Hematology & Oncology|August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual diseaseJonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Nature Communications|October 4, 2017
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemiaMelanie Märklin, Jonas S Heitmann, Alexander R Fuchs, et al.
Cancer Discovery|May 20, 2021
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with CancerTatjana Bilich, Malte Roerden, Yacine Maringer, et al.
EMBO Molecular Medicine|December 29, 2020
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancerLatifa Zekri, Fabian Vogt, Lukas Osburg, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsClaudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Frontiers in Immunology|December 11, 2024
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patientsJonas S Heitmann, Susanne Jung, Marcel Wacker, et al.
Clinical Therapeutics|February 7, 2026
Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19Maddalena Marconato, Christopher Hackenbruch, Simon Jäger, et al.
Nature Communications|November 18, 2023
TOF<sub>IMS</sub> mass spectrometry-based immunopeptidomics refines tumor antigen identificationNaomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
Nature|November 23, 2021
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunityJonas S Heitmann, Tatjana Bilich, Claudia Tandler, et al.
Pageof 7